1. Academic Validation
  2. Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands

Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands

  • ChemMedChem. 2016 Mar 17;11(6):556-61. doi: 10.1002/cmdc.201500551.
James J Sahn 1 Timothy R Hodges 1 Jessica Z Chan 1 Stephen F Martin 2
Affiliations

Affiliations

  • 1 Department of Chemistry, University of Texas at Austin, 105 East 24th Street, Stop A5300, Austin, TX, 78712, USA.
  • 2 Department of Chemistry, University of Texas at Austin, 105 East 24th Street, Stop A5300, Austin, TX, 78712, USA. sfmartin@mail.utexas.edu.
Abstract

A novel structural class with high affinity and subtype selectivity for the Sigma 2 Receptor has been discovered. Preliminary structure-affinity relationship data are presented showing that 8-substituted 1,3,4,5-tetrahydro-1,5-methanobenzazepine (norbenzomorphan) derivatives elicit modest to high selectivity for the sigma 2 over the Sigma 1 Receptor subtype. Indeed, piperazine analogue 8-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)-1,3,4,5-tetrahydro-1,5-methanobenzazepine-2-carboxylate (SAS-1121) is 574-fold selective for the sigma 2 over the Sigma 1 Receptor, thereby establishing it as one of the more subtype-selective sigma 2 binding ligands reported to date. Emerging evidence has implicated the Sigma 2 Receptor in multiple health disorders, so the drug-like characteristics of many of the selective Sigma 2 Receptor ligands disclosed herein, coupled with their structural similarity to frameworks found in known drugs, suggest that norbenzomorphan analogues may be promising candidates for further development into drug leads.

Keywords

1,5-methanobenzazepines; Sig2R/PGRMC1; norbenzomorphans; sigma 2 receptors.

Figures
Products